{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"51"}]}],"title":"Any AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"}]}],"title":"Any SAE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"63"}],"units":"Participants"}],"description":"An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or is a congenital anomaly or birth defect. Medical or scientific judgment should be exercised in other situations.","groups":[{"description":"In Part 1, participants aged between 6 and 17 years with a body weight \\<27 kg received placebo 37.5 mg QD, and those with a body weight \\>=27 kg received placebo 50 mg QD. Participants of East Asian ancestry received a starting dose of placebo 25 mg QD. Participants aged between 1 and 5 years received placebo 1.2 mg/kg QD; participants of East Asian ancestry received a starting dose of placebo 0.8 mg/kg/day.","id":"OG000","title":"Part 1 (Randmoized Period) -Placebo"},{"description":"In Part 1, participants aged between 6 and 17 years with a body weight \\<27 kg received eltrombopag 37.5 mg QD, and those with a body weight \\>=27 kg received eltrombopag 50 mg QD. Participants of East Asian ancestry received a starting dose of eltrombopag 25 mg QD. Participants aged between 1 and 5 years received eltrombopag 1.2 mg/kg QD; participants of East Asian ancestry received a starting dose of eltrombopag 0.8 mg/kg/day.","id":"OG001","title":"Part 1 (Randomized Period) - Eltrombopag"}],"paramType":"NUMBER","populationDescription":"Safety Population: all participants who received at least one dose of the investigational product","reportingStatus":"POSTED","timeFrame":"From Day 1 of Treatment up to Week 13 of Part 1+ 1 day","title":"Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During Part 1","type":"SECONDARY","unitOfMeasure":"Participants"}